Plasma Homocysteine after Insulin Infusion in Type II Diabetic Patients with and without Methionine Intolerance

Experimental and Clinical Endocrinology and Diabetes

Volumn 112, Issue 1, 2004, Pages 44-51

  Ventura, Paola ^a   Panini, R ^a   Emiliani, S ^a   Salvioli, G ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Diabetes; Homocysteine; Homocysteine cysteine ratio; Insulin; Methionine intolerance; Transsulfuration; Vitamin B6

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BIOINSULIN R; CYSTATHIONINE BETA SYNTHASE; CYSTEINE; HEMOGLOBIN A1C; HOMOCYSTEINE; INSULIN; METHIONINE; PYRIDOXINE; SOMATOSTATIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; INSULIN INFUSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SULFATION;

BLOOD GLUCOSE; CYSTEINE; DIABETES MELLITUS, TYPE 2; DNA; FEMALE; FOLIC ACID; GLUCOSE CLAMP TECHNIQUE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; INSULIN; MALE; METHIONINE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POINT MUTATION; POLYMERASE CHAIN REACTION; VITAMIN B 12; VITAMIN B 6;

EID: 1242295147     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-815726     Document Type: Article

References (66)

1. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995; 24: 704-709
2. Bailey AL, Wright AJ, Southon S. High performance liquid chromatography method for the determination of pyridoxal-5-phosphate in human plasma: how appropriate are cut-off values for vitamin B6 deficiency? Eur J Clin Nutr 1999; 53: 448-455
3. Beylot M, Chambrier C, Moneger A, Cohen R. Effects of small variations in insulin and glucagon levels on plasma aminoacids concentrations. Diabete Metab 1989; 15: 38-44
4. Blom HJ. Genetic determinants of hyperhomocysteinaemia: the roles of cystathionine beta-synthase and 5,10-methylenetetrahydrofolate reductase. Eur J Pediatr 2000; 159 (Suppl 3): S208-212
5. Blom HJ, Verhoef DP. Hyperhomocysteinemia, MTHFR, and risk of vascular disease. Circulation 2000; 101: E171; discussion E173
6. Boddie AM, Steen MT, Sullivan KM, Pasquali M, Dembure PP, Coates RJ, Elsas LJ, II. Cystathionine-beta-synthase deficiency: detection of heterozygotes by the ratios of homocysteine to cysteine and folate. Metabolism 1998; 47: 207-211
7. Boers GH, Smals AG, Trijbels FJ, Fowler B, Bakkeren JA, Schoonderwaldt HC, Kleijer WJ, Kloppenborg PW. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985; 313: 709-715
8. Bostom AG, Jacques PF, Nadeau MR, Williams RR, Ellison RC, Selhub J. Post-methionine load hyperhomocysteinemia in persons with normal fasting total plasma homocysteine: initial results from the NHLBI Family Heart Study. Atherosclerosis 1995; 116: 147-151
9. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-1057
10. Brattstrom L, Israelsson B, Norrving B, Bergqvist D, Thorne J, Hultberg B, Hamfelt A. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis 1990; 81: 51-60
11. Brattstrom L, Lindgren A, Israelsson B, Malinow MR, Norrving B, Upson B, Hamfelt A. Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors. Eur J Clin Invest 1992; 22: 214-221
12. Carlsen SM, Folling I, Grill V, Bjerve KS, Schneede J, Refsum H. Metformin increases total serum homocysteine levels in non-diabetic male patients with coronary heart disease. Scand J Clin Lab Invest 1997; 57: 521-527
13. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-1155
14. Cornwell PE, Morgan SL, Vaughn WH. Modification of a high-performance liquid chromatographic method for assay of homocysteine in human plasma. J Chromatogr 1993; 617: 136-139
15. Coull BM, Malinow MR, Beamer N, Sexton G, Nordt F, de Garmo P. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke 1990; 21: 572-576
16. Cronin CC, McPartlin JM, Barry DG, Ferriss JB, Scott JM, Weir DG. Plasma homocysteine concentrations in patients with type 1 diabetes. Diabetes Care 1998; 21: 1843-1847
17. de Jong SC, Stehouwer CD, Mackaay AJ, van den Berg M, Bulterijs EJ, Visser FC, Bax J, Rauwerda JA. High prevalence of hyperhomocysteinemia and asymptomatic vascular disease in siblings of young patients with vascular disease and hyperhomocysteinemia. Arterioscler Thromb Vasc Biol 1997; 17: 2655-2662
18. de Jong SC, Stehouwer CD, van den Berg M, Kostense PJ, Alders D, Jakobs C, Pals G, Rauwerda JA. Determinants of fasting and post-methionine homocysteine levels in families predisposed to hyperhomocysteinemia and premature vascular disease. Arterioscler Thromb Vasc Biol 1999; 19: 1316-1324
19. Domagala TB, Libura M, Szczeklik A. Hyperhomocysteinemia following oral methionine load is associated with increased lipid peroxidation. Thromb Res 1997; 87: 411-416
20. Drzewoski J, Czupryniak L, Chwatko G, Bald E. Total plasma homocysteine and insulin levels in type 2 diabetic patients with secondary failure to oral agents. Diabetes Care 1999; 22: 2097-2099
21. Engbersen AM, Franken DG, Boers GH, Stevens EM, Trijbels FJ, Blom HJ. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 1995; 56: 142-150
22. Fonseca VA, Mudaliar S, Schmidt B, Fink LM, Kern PA, Henry RR. Plasma homocysteine concentrations are regulated by acute hyperinsulinemia in nondiabetic but not type 2 diabetic subjects. Metabolism 1998; 47: 686-689
23. Fortin LJ, Genest J Jr. Measurement of homocyst(e)ine in the prediction of arteriosclerosis. Clin Biochem 1995; 28: 155-162
24. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113
25. Glanville NT, Anderson GH. Altered methionine metabolism in streptozotocin-diabetic rats. Diabetologia 1984; 27: 468-471
26. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GH, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales Luis AC, Parrot-Rouland FM, Tan KS, Higgins I, Garcon D, Andria G et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997; 277: 1775-1781
27. Guttormsen AB, Ueland PM, Nesthus I, Nygard O, Schneede J, Vollset SE, Refsum H. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (> or = 40 micromol/liter). The Hardaland Homocysteine Study. J Clin Invest 1996; 98: 2174-2183
28. Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58: 731-741
29. Harmon DL, Woodside JV, Yarnell JW, McMaster D, Young IS, McCrum EE, Gey KF, Whitehead AS, Evans AE. The common 'thermolabile' variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. QJM 1996; 89: 571-577
30. Hoogeveen EK, Kostense PJ, Beks PJ, Mackaay AJ, Jakobs C, Bouter LM, Heine RJ, Stehouwer CD. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol 1998; 18: 133-138
31. Hoogeveen EK, Kostense PJ, Jakobs C, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Circulation 2000; 101: 1506-1511
32. Hultberg B, Agardh CD, Agardh E, Lovestam-Adrian M. Poor metabolic control, early age at onset, and marginal folate deficiency are associated with increasing levels of plasma homocysteine in insulin-dependent diabetes mellitus. A five-year follow-up study. Scand J Clin Lab Invest 1997; 57: 595-600
33. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93: 7-9
34. Kang SS, Wong PW, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 1992; 12: 279-298
35. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-2410
36. Kluijtmans LA, van den Heuvel LP, Boers GH, Frosst P, Stevens EM, van Oost BA, den Heijer M, Trijbels FJ, Rozen R, Blom HJ. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58: 35-41
37. Lanfredini M, Fiorina P, Peca MG, Veronelli A, Mello A, Astorri E, Dall'Aglio P, Craveri A. Fasting and post-methionine load homocyst(e)ine values are correlated with microalbuminuria and could contribute to worsening vascular damage in non-insulin-dependent diabetes mellitus patients. Metabolism 1998; 47: 915-921
38. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996; 98: 5-7
39. Luzi L, Petrides AS, De Fronzo RA. Different sensitivity of glucose and amino acid metabolism to insulin in NIDDM. Diabetes 1993; 42: 1868-1877
40. Malinow MR. Hyperhomocyst(e)inemia. A common and easily reversible risk factor for occlusive atherosclerosis. Circulation 1990; 81: 2004-2006
41. Mason JB, Miller JW. The effects of vitamins B12, B6, and folate on blood homocysteine levels. Ann N Y Acad Sci 1992; 669: 197-203; discussion 203-194
42. Miller JW, Ribaya-Mercado JD, Russell RM, Shepard DC, Morrow FD, Cochary EF, Sadowski JA, Gershoff SN, Selhub J: Effect of vitamin B-6 deficiency on fasting plasma homocysteine concentrations. Am J Clin Nutr 1992; 55: 1154-1160
43. Morrow LE, Grimsley EW. Long-term diuretic therapy in hypertensive patients: effects on serum homocysteine, vitamin B6, vitamin B12, and red blood cell folate concentrations. South Med J 1999; 92: 866-870
44. Mudd SHLH. Disorders in transsulfuration. In: Stanbury JBWJ, Fredrickson DS, Goldstein JL, Brown MS (eds). Metabolic Bases of Inherited Diseases. 5th ed. New York: McGraw-Hill Book Co., 1995: 1279-1327
45. Munshi MN, Stone A, Fink L, Fonseca V. Hyperhomocysteinemia following a methionine load in patients with non-insulin-dependent diabetes mellitus and macrovascular disease. Metabolism 1996; 45: 133-135
46. Olszewski AJ, McCully KS. Homocysteine metabolism and the oxidative modification of proteins and lipids. Free Radic Biol Med 1993; 14: 683-693
47. Ou K, Wilkins MR, Yan JX, Gooley AA, Fung Y, Sheumack D, Williams KL. Improved high-performance liquid chromatography of amino acids derivatised with 9-fluorenylmethyl chloroformate. J Chromatogr A 1996; 723: 219-225
48. Pijl H, Potter van Loon BJ, Toornvliet AC, Radder JK, Onkenhout W, Frolich M, Meinders AE. Insulin-induced decline of plasma amino acid concentrations in obese subjects with and without non-insulin-dependent diabetes. Metabolism 1994; 43: 640-646
49. Refsum H, Ueland PM. Clinical significance of pharmacological modulation of homocysteine metabolism. Trends Pharmacol Sci 1990; 11: 411-416
50. Reis RP, Azinheira J, Reis HP, Bordalo A, Santos L, Adao M, Pina JE, Ferreira NC, Luis AS. Homocysteinaemia after methionine overload as a coronary artery disease risk factor: importance of age and homocysteine levels. Coron Artery Dis 1995; 6: 851-856
51. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2000; 23 (Suppl 1): S4-19
52. Robillon JF, Canivet B, Candito M, Sadoul JL, Jullien D, Morand P, Chambon P, Freychet P. Type 1 diabetes mellitus and homocyst(e)ine. Diabete Metab 1994; 20: 494-496
53. Rozen R. Genetic predisposition to hyperhomocysteinemia: deficiency of methylenetetrahydrofolate reductase (MTHFR). Thromb Haemost 1997; 78: 523-526
54. Selhub J, Miller JW. The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 1992; 55: 131-138
55. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877-881
56. Swendseid ME, Tuttle SG, Drenick EJ, Joven CB, Massey FJ. Plasma amino acid response to glucose administration in various nutritive states. Am J Clin Nutr 1967; 20: 243-249
57. Tsai MY, Garg U, Key NS, Hanson NQ, Suh A, Schwichtenberg K. Molecular and biochemical approaches in the identification of heterozygotes for homocystinuria. Atherosclerosis 1996; 122: 69-77
58. Tsai MY, Welge BG, Hanson NQ, Bignell MK, Vessey J, Schwichtenberg K, Yang F, Bullemer FE, Rasmussen R, Graham KJ. Genetic causes of mild hyperhomocysteinemia in patients with premature occlusive coronary artery diseases. Atherosclerosis 1999; 143: 163-170
59. van den Berg M, Franken DG, Boers GH, Blom HJ, Jakobs C, Stehouwer CD, Rauwerda JA. Combined vitamin B6 plus folic acid therapy in young patients with arteriosclerosis and hyperhomocysteinemia. J Vasc Surg 1994; 20: 933-940
60. van den Berg M, Stehouwer CD, Bierdrager E, Rauwerda JA. Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease. Arterioscler Thromb Vasc Biol 1996; 16: 165-171
61. Ventura P, Panini R, Verlato C, Scarpetta G, Salvioli G. Peroxidation indices and total antioxidant capacity in plasma during hyperhomocysteinemia induced by methionine oral loading. Metabolism 2000; 49: 225-228
62. Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 1980; 18: 113-121
63. Welch GN, Upchurch G Jr., Loscalzo J. Hyperhomocyst(e)inemia and atherothrombosis. Ann N Y Acad Sci 1997a; 811: 48-58; discussion 58-49
64. Welch GN, Upchurch GR Jr., Loscalzo J. Homocysteine, oxidative stress, and vascular disease. Hosp Pract (Off Ed) 1997 b; 32: 81-92
65. Wilcken DE, Wilcken B, Dudman NP, Tyrrell PA. Homocystinuria - the effects of betaine in the treatment of patients not responsive to pyridoxine. N Engl J Med 1983; 309: 448-453
66. Zinneman HH, Nuttall FQ, Goetz FC. Effect of endogenous insulin on human amino acid metabolism. Diabetes 1966; 15: 5-8